- Home
- OKUR vs IMUX Comparison
OKUR vs IMUX Comparison
Compare OKUR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OKUR
- IMUX
- Stock Information
- Founded
- OKUR 2011
- IMUX 2016
- Country
- OKUR United States
- IMUX United States
- Employees
- OKUR N/A
- IMUX N/A
- Industry
- OKUR
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- OKUR
- IMUX Health Care
- Exchange
- OKUR NYSE
- IMUX Nasdaq
- Market Cap
- OKUR 76.6M
- IMUX 90.3M
- IPO Year
- OKUR N/A
- IMUX N/A
- Fundamental
- Price
- OKUR $2.89
- IMUX $0.98
- Analyst Decision
- OKUR Strong Buy
- IMUX Strong Buy
- Analyst Count
- OKUR 4
- IMUX 6
- Target Price
- OKUR $32.25
- IMUX $13.20
- AVG Volume (30 Days)
- OKUR 49.1K
- IMUX 661.4K
- Earning Date
- OKUR 05-14-2025
- IMUX 05-07-2025
- Dividend Yield
- OKUR N/A
- IMUX N/A
- EPS Growth
- OKUR N/A
- IMUX N/A
- EPS
- OKUR N/A
- IMUX N/A
- Revenue
- OKUR N/A
- IMUX N/A
- Revenue This Year
- OKUR N/A
- IMUX N/A
- Revenue Next Year
- OKUR N/A
- IMUX N/A
- P/E Ratio
- OKUR N/A
- IMUX N/A
- Revenue Growth
- OKUR N/A
- IMUX N/A
- 52 Week Low
- OKUR $2.57
- IMUX $0.83
- 52 Week High
- OKUR $20.00
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- OKUR N/A
- IMUX 45.24
- Support Level
- OKUR N/A
- IMUX $0.86
- Resistance Level
- OKUR N/A
- IMUX $1.01
- Average True Range (ATR)
- OKUR 0.00
- IMUX 0.09
- MACD
- OKUR 0.00
- IMUX -0.01
- Stochastic Oscillator
- OKUR 0.00
- IMUX 42.53
About OKUR ONKURE THERAPEUTICS INC
OnKure Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing top-tier precision medicines that target biologically validated drivers of cancers that are underserved by available therapies. It has a pipeline of tumor-agnostic candidates that are designed to achieve optimal efficacy and tolerability.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.